George A. Eldridge - 02 Apr 2021 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: Chief Financial Officer and Treasurer
Signature
/s/ George A. Eldridge
Issuer symbol
JBIO
Transactions as of
02 Apr 2021
Net transactions value
$0
Form type
4
Filing time
01 Jul 2021, 18:29:43 UTC
Next filing
29 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +50,850 $0.000000 50,850 02 Apr 2021 Common Stock 50,850 $2.14 Direct F1, F2, F3
transaction AVTE Stock Option (Right to Buy) Award $0 +98,676 $0.000000 98,676 02 Apr 2021 Common Stock 98,676 $2.14 Direct F1, F2, F4
transaction AVTE Stock Option (Right to Buy) Award $0 +76,900 $0.000000 76,900 29 Jun 2021 Common Stock 76,900 $14.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
F2 This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3 25% of this option shall vest and become exercisable on March 22, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F5 25% of this option shall vest and become exercisable on June 29, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer